Bipolar androgen therapy: A novel therapeutic strategy for castration-resistant prostate cancer.
- Author:
Yong-Hui HU
1
;
Jian-Chao GUO
1
;
Meng ZHANG
2
Author Information
1. Department of Endocrinology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China.
2. Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230031, China.
- Publication Type:Journal Article
- Keywords:
androgen receptor;
castration-resistant prostate cancer;
bipolar androgen therapy
- MeSH:
Androgen Antagonists;
therapeutic use;
Hormone Replacement Therapy;
methods;
Humans;
Male;
Prostate-Specific Antigen;
blood;
Prostatic Neoplasms, Castration-Resistant;
blood;
drug therapy;
Receptors, Androgen;
Testosterone;
administration & dosage;
blood
- From:
National Journal of Andrology
2017;23(12):1138-1140
- CountryChina
- Language:Chinese
-
Abstract:
Bipolar androgen therapy (BAT), as a new therapeutic strategy for castration-resistant prostate cancer (CRPC), can significantly reduce the level of prostate-specific antigen (PSA) for prostate cancer patients and has exhibited an excellent safety profile with no serious adverse events. Based on the clinical trials recently published at home and abroad, this article reviews the background, action mechanism, development, and prospect of BAT.
